The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.75
Bid: 32.50
Ask: 33.00
Change: -0.50 (-1.50%)
Spread: 0.50 (1.538%)
Open: 33.00
High: 33.25
Low: 32.75
Prev. Close: 33.25
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

16 Sep 2020 07:00

RNS Number : 0953Z
Duke Royalty Limited
16 September 2020
 

16 September 2020

 

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Trading Update

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, is pleased to provide the following trading update for its second financial quarter ending 30 September 2020 ("Q2 FY21").

The Company confirms that the general upturn experienced in the underlying trading of its royalty partners, as referred to in its Q1 FY21 trading update, has continued into Q2 FY21.

Based on current expectations, the Company expects that cash revenue for the quarter, being cash distributions from its Royalty Partners and cash gains from sales of equity assets, will total £2.4 million versus £2.0 million in Q1 FY21.

To put this into context, Duke reported its record quarterly cash revenue in Q4 FY20, when it generated cash receipts of over £2.8m, representing a normalised pre-COVID trading environment.

Subsequently, and as previously reported, the Company proactively entered into forbearance agreements in Q1 FY21 with those Royalty Partners which had been the most affected by the Covid-19 pandemic, in order to give them the financial flexibility to manage their way through the financial challenges that they were experiencing. These forbearance agreements initially covered the period from 1 April 2020 to 30 September 2020 and resulted in a short-term reduction in cash revenue for Duke, with the forgone revenue for the first six months of the pandemic either being accrued, capitalised or equitised.

However, as these agreements expire, Duke is cautiously optimistic that it will be able to announce a further increase in quarterly cash revenue for the period Q3 FY21.

Neil Johnson, CEO of Duke Royalty, said:

"It is very pleasing to see the increased cash revenue generated by the Company's royalty partners in Q2 FY21 over Q1 FY21. While the pandemic's effects are felt throughout all aspects of the economy and general life, I am proud of the team's response to the crisis, and of the resilience of our royalty partners and the royalty business model. We are focused on continuing to work with our existing royalty partners while also looking for new opportunities in which to deploy our capital."

 

***ENDS***

 

For further information, please contact www.dukeroyalty.com, or contact:

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon Brookes / Hugo Evans

 

+44 (0) 1481 741 240

Cenkos Securities plc 

(Nominated Adviser and Broker)

 

Stephen Keys / Callum Davidson / Julian Morse / Michael Johnson

 

+44 (0) 207 397 8900

Newgate Communications (PR)

Elisabeth Cowell/ Ian Silvera/ Megan Kovach

+ +44 (0) 20 3757 6880 dukeroyalty@newgatecomms.com

 

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSTALIELII
Date   Source Headline
22nd Jun 20173:19 pmRNSFinal Results and Maiden Dividend
22nd Jun 20177:00 amRNSFinal Results
9th Jun 20177:00 amRNSRoyalty Partner Operational Update
6th Apr 20177:00 amRNSInaugural royalty financing agreement
28th Mar 20177:00 amRNSHolding(s) in Company
24th Mar 20172:55 pmRNSHolding(s) in Company
23rd Mar 20175:00 pmRNSRe-Admission and First Day of Dealings
22nd Mar 20173:45 pmRNSSch 1 Update - Duke Royalty Limited
20th Mar 20179:35 amRNSSch 1 Update - Duke Royalty Limited
17th Mar 20176:17 pmRNSResult of Fundraising
16th Mar 20175:03 pmRNSProposed Placing and Subscription
21st Feb 201711:25 amRNSSch 1 Update - Duke Royalty Limited
1st Feb 201711:00 amRNSSchedule 1 - Duke Royalty Limited
11th Jan 20177:01 amRNSAppointment of Chief Investment Officer
11th Jan 20177:00 amRNSChange of Advisors and Operational Update
17th Nov 20169:00 amRNSUnaudited interim results
1st Sep 201612:02 pmRNSResult of AGM
25th Jul 20167:00 amRNSFinal Results
29th Mar 20161:32 pmRNSSale of investments
7th Mar 20167:00 amRNSBoard Changes and Corporate Update
3rd Feb 20167:00 amRNSDirector/PDMR Shareholding
19th Jan 20169:55 amRNSChange of Adviser
14th Dec 201511:40 amRNSDirector/PDMR Shareholding
23rd Nov 20157:00 amRNSInterim results
29th Oct 20157:00 amRNSHolding(s) in Company
29th Oct 20157:00 amRNSCorrection: Appointment and Issue of Shares
28th Oct 20157:00 amRNSMr Justin Cochrane Appointment and Issue of Shares
12th Oct 20155:16 pmRNSHolding(s) in Company
17th Sep 20153:40 pmRNSFormation of Healthcare Investment Committee
14th Sep 201512:41 pmRNSHolding(s) in Company
11th Sep 20157:00 amRNSDirector share purchase
10th Sep 201512:00 pmRNSResult of AGM
7th Sep 20159:15 amRNSGrant of options
7th Sep 20157:00 amRNSPlacing
7th Sep 20157:00 amRNSCollaboration with Oliver Wyman
4th Aug 201512:21 pmRNSChanges to NAV Reporting
27th Jul 20154:12 pmRNSResults for the year ended 31 March 2015
16th Jun 201511:36 amRNSResult of EGM
10th Jun 201511:21 amRNSHolding(s) in Company
2nd Jun 20151:57 pmRNSHolding(s) in Company
28th May 201511:00 amRNSEGM, proposed changes to board & investing policy
26th May 20159:58 amRNSHolding(s) in Company
26th May 20159:57 amRNSHolding(s) in Company
26th May 20159:56 amRNSHolding(s) in Company
26th May 20159:56 amRNSHolding(s) in Company
22nd May 20155:15 pmRNSRepayment of zero dividend preference shares
20th May 20157:00 amRNSPlacing
15th May 201511:08 amRNSSale of investment
20th Apr 20155:36 pmRNSNet Asset Value(s)
19th Jan 20154:27 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.